Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Risk Factors × Clear all
NCT05029531 2024-06-28

Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 3 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡